Trial Profile
A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs PanBlok (Primary) ; ADVAX
- Indications Influenza A virus H7N9 subtype
- Focus Pharmacodynamics
- Acronyms FLU007
- Sponsors Vaxine
- 06 May 2019 Status changed from active, no longer recruiting to completed.
- 04 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 04 May 2018 Status changed from recruiting to active, no longer recruiting.